Patents Assigned to BioSplice Therapeutics, Inc.
-
Patent number: 12134625Abstract: Pyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).Type: GrantFiled: October 12, 2022Date of Patent: November 5, 2024Assignee: BioSplice Therapeutics, Inc.Inventors: Gopi Kumar Mittapalli, Sunil Kumar K C, Chi Ching Mak, Brian Joseph Hofilena, Lewis Daniel Turner, Brian Walter Eastman, Ramkrishna Reddy Vakiti, Joseph Timothy Marakovits
-
Patent number: 12012401Abstract: Provided herein is a synthetic process for preparing a compound of Formula (1). The disclosure also provides useful intermediates and salts, amorphous and polymorph forms of the compound of Formula (1). These compounds are useful for various disease including cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, and osteoarthritis as well as Wnt-related diseases.Type: GrantFiled: March 18, 2021Date of Patent: June 18, 2024Assignee: BioSplice Therapeutics, Inc.Inventor: Sunil Kumar KC
-
Patent number: 11839679Abstract: The present disclosure relates to ?-diketone compounds, such as those having the structures: The disclosure also relates to cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for improving the aesthetic appearance of a subject's skin, for example, improving one or more of skin tone, radiance, clarity, tautness, skin firmness, plumpness, suppleness, softness, skin texture, skin texturization and moisturization, appearance of skin contours, appearance of hollow cheeks, appearance of sunken, baggy, or dark circles under eyes, skin luster, brightness, skin thickness, and skin elasticity and/or resiliency comprising application of the compounds or compositions disclosed.Type: GrantFiled: June 29, 2021Date of Patent: December 12, 2023Assignee: BioSplice Therapeutics, Inc.Inventors: John Hood, Sunil Kumar Kc, Osman Kibar, Charlene F. Barroga
-
Patent number: 11819499Abstract: Provided are single-dose, ready-to-use formulations and methods for preparing the formulations that include a compound of Formula (I) including pharmaceutically acceptable salts and amorphous and polymorph forms thereof.Type: GrantFiled: July 26, 2022Date of Patent: November 21, 2023Assignee: BioSplice Therapeutics, Inc.Inventor: Luis A. Dellamary
-
Patent number: 11780823Abstract: Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.Type: GrantFiled: June 14, 2021Date of Patent: October 10, 2023Assignee: BioSplice Therapeutics, Inc.Inventors: John Hood, Sunil Kumar KC
-
Patent number: 11713320Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: GrantFiled: December 30, 2020Date of Patent: August 1, 2023Assignee: BioSplice Therapeutics, Inc.Inventors: Sunil Kumar Kc, Chi Ching Mak, Gopi Kumar Mittapalli, Brian Joseph Hofilena, Brian Walter Eastman, Jianguo Cao, Chandramouli Chiruta, Venkataiah Bollu
-
Patent number: 11697649Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.Type: GrantFiled: February 5, 2021Date of Patent: July 11, 2023Assignee: BioSplice Therapeutics, Inc.Inventors: John Hood, David Mark Wallace, Sunil Kumar KC
-
Methods of using indazole-3-carboxamides and their use as Wnt/?-catenin signaling pathway inhibitors
Patent number: 11684615Abstract: This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.Type: GrantFiled: June 29, 2020Date of Patent: June 27, 2023Assignee: BioSplice Therapeutics, Inc.Inventors: Vishal Deshmukh, Eric Anthony Murphy, John Hood -
Patent number: 11673885Abstract: The present disclosure provides ?-diketones or analogs thereof, that activate Wnt/?-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.Type: GrantFiled: April 27, 2021Date of Patent: June 13, 2023Assignee: BioSplice Therapeutics, Inc.Inventors: Sunil Kumar KC, David Mark Wallace, John Hood, Charlene F. Barroga
-
Patent number: 11673881Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: GrantFiled: October 6, 2021Date of Patent: June 13, 2023Assignee: BioSplice Therapeutics, Inc.Inventors: Sunil Kumar KC, Gopi Kumar Mittapalli, Brian Joseph Hofilena, Joseph Timothy Marakovits, Chandramouli Chiruta, Chi Ching Mak, Jianguo Cao
-
Patent number: 11667632Abstract: Indazole compounds for treating various diseases and pathologies are provided. More particularly, the use of an indazole compound or analogs thereof, in the treatment of inflammatory diseases or disorders is provided.Type: GrantFiled: December 4, 2020Date of Patent: June 6, 2023Assignee: BioSplice Therapeutics, Inc.Inventors: John Hood, David Mark Wallace, Sunil Kumar KC, Yusuf Yazici, Christopher Swearingen, Luis A Dellamary
-
Patent number: 11560378Abstract: Provided are compositions and methods for treating osteoarthritis including intra-articular administration of a compound of Formula (I) including amorphous and polymorph forms thereof.Type: GrantFiled: December 1, 2020Date of Patent: January 24, 2023Assignee: BioSplice Therapeutics, Inc.Inventors: John Hood, David Mark Wallace, Sunil Kumar KC, Yusuf Yazici, Christopher Swearingen, Luis A Dellamary
-
Patent number: 11548872Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.Type: GrantFiled: January 22, 2021Date of Patent: January 10, 2023Assignee: BioSplice Therapeutics, Inc.Inventors: Sunil Kumar KC, Chi Ching Mak, Brian Walter Eastman, Jianguo Cao, Venkataiah Bollu, Gopi Kumar Mittapalli, Chandramouli Chiruta
-
Patent number: 11446288Abstract: Provided are single-dose, ready-to-use formulations and methods for preparing the formulations that include a compound of Formula (I) including pharmaceutically acceptable salts and amorphous and polymorph forms thereof.Type: GrantFiled: July 27, 2020Date of Patent: September 20, 2022Assignee: BioSplice Therapeutics, Inc.Inventor: Luis A. Dellamary
-
Patent number: 11174244Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.Type: GrantFiled: December 26, 2019Date of Patent: November 16, 2021Assignee: BioSplice Therapeutics, Inc.Inventors: Sunil Kumar KC, Gopi Kumar Mittapalli, Brian Joseph Hofilena, Joseph Timothy Marakovits, Chandramouli Chiruta, Chi Ching Mak, Jianguo Cao
-
Patent number: 11077046Abstract: The present disclosure relates to compounds, cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or or wrinkles of skin comprising application of the compounds or compositions disclosed.Type: GrantFiled: August 7, 2019Date of Patent: August 3, 2021Assignee: BioSplice Therapeutics, Inc.Inventors: John Hood, Sunil Kumar KC, Osman Kibar, Charlene F. Barroga
-
Patent number: 11066388Abstract: Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.Type: GrantFiled: September 19, 2019Date of Patent: July 20, 2021Assignee: BioSplice Therapeutics, Inc.Inventors: John Hood, Sunil Kumar KC